Cantor Fitzgerald Forecasts Cytokinetics FY2025 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Cytokinetics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the biopharmaceutical company will post earnings of ($4.75) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.23) per share.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.09). The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $1.21 million. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period in the previous year, the business posted ($1.35) earnings per share.

Several other brokerages have also commented on CYTK. Mizuho raised their price objective on Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Royal Bank of Canada boosted their price target on shares of Cytokinetics from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of Cytokinetics in a research report on Tuesday. JMP Securities reissued a “market outperform” rating and set a $78.00 target price on shares of Cytokinetics in a research note on Tuesday, January 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a research note on Monday, December 2nd. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $83.64.

Cytokinetics Trading Up 0.2 %

Shares of Cytokinetics stock opened at $45.82 on Wednesday. The firm has a 50-day simple moving average of $49.12 and a two-hundred day simple moving average of $53.08. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. Cytokinetics has a fifty-two week low of $44.49 and a fifty-two week high of $84.92. The company has a market cap of $5.41 billion, a P/E ratio of -8.52 and a beta of 0.82.

Insiders Place Their Bets

In related news, Director Wendall Wierenga sold 4,452 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $52.25, for a total value of $232,617.00. Following the sale, the director now directly owns 24,559 shares in the company, valued at approximately $1,283,207.75. The trade was a 15.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $51.91, for a total transaction of $378,943.00. Following the sale, the executive vice president now owns 114,920 shares of the company’s stock, valued at approximately $5,965,497.20. This represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 54,216 shares of company stock valued at $2,799,276. Insiders own 3.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its position in Cytokinetics by 27.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 148,561 shares of the biopharmaceutical company’s stock valued at $8,049,000 after purchasing an additional 32,372 shares in the last quarter. Mutual of America Capital Management LLC increased its stake in shares of Cytokinetics by 12.3% during the second quarter. Mutual of America Capital Management LLC now owns 65,645 shares of the biopharmaceutical company’s stock worth $3,557,000 after buying an additional 7,208 shares during the period. Amalgamated Bank raised its holdings in Cytokinetics by 8.0% in the second quarter. Amalgamated Bank now owns 55,397 shares of the biopharmaceutical company’s stock valued at $3,001,000 after acquiring an additional 4,099 shares in the last quarter. Pacer Advisors Inc. lifted its stake in Cytokinetics by 21.2% in the second quarter. Pacer Advisors Inc. now owns 18,720 shares of the biopharmaceutical company’s stock worth $1,014,000 after acquiring an additional 3,271 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in Cytokinetics by 8.1% in the second quarter. Sei Investments Co. now owns 63,009 shares of the biopharmaceutical company’s stock worth $3,414,000 after acquiring an additional 4,695 shares during the last quarter.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.